

## SPECIALTY QUANTITY LIMIT PROGRAM

### NUCALA (mepolizumab)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Nucala 100 mg single-dose vial	3 per 28 days	Severe asthma: <ul style="list-style-type: none"> <li>• Age 12 years or older: 100 mg every 4 weeks</li> <li>• Age 6 to 11 years: 40 mg every 4 weeks</li> </ul> Eosinophilic granulomatosis with polyangiitis: 300 mg (three 100 mg injections) every 4 weeks
Nucala 100 mg/mL single-dose prefilled safety syringe	3 per 28 days	
Nucala 100 mg/mL single-dose prefilled autoinjector	3 per 28 days	

#### III. REFERENCES

- Nucala [package insert]. Research Triangle Park, NC: GlaxoSmithKline, Inc.; September 2019.